Acasti Pharma Inc  

(Public, CVE:APO)   Watch this stock  
Find more results for APO
Jul 11 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.88 - 4.32
Open     -
Vol / Avg. 0.00/56,480.00
Mkt cap 119.01M
P/E     -
Div/yield     -
EPS -0.14
Shares 106.26M
Beta 1.45
Inst. own     -

Key stats and ratios

Q1 (Feb '14) 2014
Net profit margin -1276.18% -2318.25%
Operating margin -1124.87% -2156.14%
EBITD margin - -1801.97%
Return on average assets -28.78% -40.18%
Return on average equity -38.05% -54.00%
CDP Score - -


Suite 100, 545 Promenade du Centropolis
+1-450-6864555 (Phone)
+1-450-6862505 (Fax)


Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company�s product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.

Officers and directors

Ronald Denis Independent Chairman of the Board
Andre Godin Interim President and Chief Executive Officer
Pierre Lemieux Ph.D. Chief Operating Officer
Harlan W. Waksal M.D. Executive Vice President - Business and Scientific Affairs
Age: 60
Tina Sampalis MD, Ph.D. Chief Global Strategy Officer
Henri Harland Secretary, Director
Reed V. Tuckson M.D. Independent Director
Age: 48